Yichang Sanxia Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of humanwell Pharmaceutical Group. The company is a national high-tech enterprise. It is a comprehensive biopharmaceutical enterprise that studies and produces antibiotic raw materials, amino acid series high-capacity injections and animal pharmaceutical preparations. In recent years, the company has successively won the titles of "national intellectual property advantage enterprise", "Hubei pharmaceutical industry API export-oriented excellent enterprise", "Hubei export enterprise top 10 foreign exchange earning enterprises", "Hubei science and technology giant", "Hubei contract abiding and trustworthy enterprise", "Hubei industrialization integration demonstration enterprise" and so on. The company is a large global supplier of neomycin sulfate API. The subdivided product line covers neomycin sulfate for animals, Fraxinus sulfate, neomycin sulfate for prescription people in the United States, etc. the products have passed the certification of FDA and EU CEP, with a global market share of more than 80%. Neomycin sulfate has won the Title of "single champion product" in the national manufacturing industry. The company is also one of the earliest manufacturers of amino acid high-volume injections in China. At present, it mainly produces compound amino acid infusion and other basic infusion with product specifications of 3AA、6AA、9AA、15AA、17AA、17AA-I、18AA, and the product specifications of various soft bags and glass bottles have reached 46. Among them, "Three Gorges brand" series amino acid high-volume injections are recognized as "famous brand products" and "high-quality products" in Hubei Province. The sales volume of compound amino acid injection 3AA accounts for more than 50% in China. In the next 3-5 years, the company will optimize the product structure, focus on the high-end market and realize strategic transformation and upgrading based on the advantages of neomycin sulfate technology and resources. Three major drug systems with veterinary drug as the core and veterinary drug related system as the core. The company continues to strengthen product development, enrich and optimize the product system structure, including a series of new veterinary drugs, new human therapeutic infusion products and other advanced products, which are under development or preparation for listing.